Your browser doesn't support javascript.
loading
Immunity of two novel hepatitis C virus polyepitope vaccines.
Feng, Tian; Li, Mingzhi; Zhang, Lirong; Li, Sha; Yang, Zibing; Kang, Lumei; Guo, Yunli; Kong, Lingbao; Wang, Ting.
Afiliação
  • Feng T; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China.
  • Li M; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China.
  • Zhang L; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China.
  • Li S; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China.
  • Yang Z; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China.
  • Kang L; College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, China; Center for Laboratory Animal Science, Nanchang University, Nanchang, Jiangxi, China.
  • Guo Y; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China.
  • Kong L; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China. Electron
  • Wang T; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China. Electron
Vaccine ; 40(43): 6277-6287, 2022 10 12.
Article em En | MEDLINE | ID: mdl-36150975
Hepatitis C virus (HCV) infection remains a serious public health burden around the world. So far there is no effective vaccine against this virus. Neutralizing antibody (NAb) responses to the epitopes within HCV E1 and E2 proteins are related to the resolution of hepatitis C infection. E. coli heat-labile enterotoxin B subunit (LTB) has been described as potent immunity adjuvants. In this study, we constructed recombinant pET vectors: pET-R9-Bp (B cell polyepitopes) expressing 7 epitopes from HCV E1 and E2 proteins including R9 (E2384-411aa)-Bp (E1313-327aa-E2396-424aa-E2436-447aa-E2523-540aa-E2610-627aa-E2631-648aa) and pET-LTB-R9-Bp expressing LTB adjuvant in combination with R9-Bp. Recombinant proteins R9-Bp and LTB-R9-Bp were expressed successfully in E. coli and purified by the Ni-NTA column. Both R9-Bp and LTB-R9-Bp in BALB/c mice induced robust humoral immune response in the context of intraperitoneal or intramuscular immunization but not oral immunization. Intraperitoneal administration of LTB-R9-Bp induced a higher antibody titer (peak titer: 1:341000) than that of R9-Bp (peak titer: 1:85000) after the second boost (P = 0.0036 or 0.0002). However, comparable antibody peak titers were elicited for both R9-Bp and LTB-R9-Bp in intramuscular immunization albeit with significant difference (P = 0.0032) a week after the second boost. In addition, both R9-Bp and LTB-R9-Bp induced the secretion of cytokines including IFN-γ and IL-4 at similar levels. anti-sera induced by both R9-Bp and LTB-R9-Bp recognized native HCV E1 and E2 proteins. Moreover, these HCV-specific antisera inhibited significantly the entry of HCV (P < 0.0001). Taken together, these findings showed that E. coli-based both R9-Bp and LTB-R9-Bp could become promising HCV vaccines.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepacivirus Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepacivirus Idioma: En Ano de publicação: 2022 Tipo de documento: Article